Lenalidomide Tecnigen

Lenalidomide, the active ingredient in Lenalidomide Tecnigen, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of certain hematologic cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in combination therapy.

GNH USA supplies Lenalidomide Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution, with a focus on timely delivery and regulatory compliance.

Lenalidomide is employed in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow.

- Multiple myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic response in low‑risk patients. - Mantle cell lymphoma (in combination therapy): enhances overall response rates when used with other antineoplastic agents.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count leading to infection risk. - Thrombocytopenia: reduced platelet levels increasing bleeding tendency. - Anemia: lowered red blood cell count causing fatigue. - Fatigue: general feeling of tiredness. - Nausea: upset stomach and possible vomiting. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe rash or Stevens‑Johnson syndrome: skin reactions requiring immediate care. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating lenalidomide therapy, several safety considerations should be addressed.

- Blood count monitoring: perform baseline and regular CBC to detect cytopenias. - Thromboembolic risk assessment: evaluate need for prophylactic anticoagulation in high‑risk patients. - Pregnancy prevention: enforce strict contraception for women of childbearing potential. - Renal function evaluation: adjust dosing in patients with impaired kidney function. - Concomitant myelosuppressive therapy: use caution when combined with other agents that lower blood counts. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Potent P‑glycoprotein inhibitors (e.g., itraconazole): can raise plasma concentrations. - Combined use with other myelosuppressive drugs: heightens risk of severe cytopenias.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): monitor for increased bleeding risk. - CYP inducers (e.g., rifampin): may reduce drug levels. - Live attenuated vaccines: consider timing to avoid reduced vaccine efficacy.